IGFBP3 and ductal breast carcinoma in situ: In the clinical trial led by Dr. Carol Fabian (ClinicalTrials.gov Identifier: NCT00291096), serum IGF-1/IGFBP3 levels were explored to determine the relative predictive value of the established risk biomarkers for the development of DCIS and/or invasive cancer.